Identity
- Trade Name
- EPO (Erythropoietin) ELISA FDA UDI
- Generic Name
- Erythropoietin (EPO) IVD, reagent FDA UDI
- Device Name
- The EPO ELISA is intended for in vitro diagnostic use in the quantitative determination of Erythropoietin (EPO) in human serum FDA UDI
- Model / Reference
- EIA-3646 FDA UDI
- Description
- The EPO ELISA is intended for in vitro diagnostic use in the quantitative determination of Erythropoietin (EPO) in human serum FDA UDI
Identifiers
- Catalog Number
- EIA-3646 FDA UDI
- Primary DI / UDI-DI
- 04048474036466 FDA UDI
- 510(k) Number
- K992799 FDA UDI
- FDA Product Code
- GGT FDA UDI
- GMDN Term
- Erythropoietin (EPO) IVD, reagent FDA UDI
Classification
- Device Class
- Class II FDA UDI
- Regulation Number
- 864.7250 FDA UDI
- Commercial Distribution
- In Commercial Distribution FDA UDI
Clinical & Handling
Sterile
No
FDA UDI
Single Use
Yes
FDA UDI
Implantable
No
FDA UDI
Contains Latex
No
FDA UDI
Prescription Use
Yes
FDA UDI
Over-the-Counter
No
FDA UDI
Convenience Kit
Yes
FDA UDI
Combination Product
No
FDA UDI
HCT/P
No
FDA UDI
Premarket Exempt
No
FDA UDI
Lot / Batch Number
Yes
FDA UDI
Serial Number
No
FDA UDI
Expiration Date
Yes
FDA UDI
Manufacturing Date
Yes
FDA UDI
Category: Erythropoietin (EPO) IVD, reagent
EPO (Erythropoietin) ELISA by DRG Instruments Gesellschaft mit beschränkter Haftung — Class II — FDA UDI — listed in FDA GUDID — regulatory data on deviCERTS
Similar devices
Also classified as Erythropoietin (EPO) IVD, reagent.
- EPO (Erythropoietin) ELISA — DRG International, Inc. · Class II
Cleared under the same submission
K992799 also covers:
Authorization Coverage (1 country)
Regulatory Authorizations
United States Pending data
FDA UDI
| Source | Region | Type | Cert / Approval No. | Class | Status |
|---|---|---|---|---|---|
| FDA UDI | United States | FDA UDI | Registered in GUDID | Class II | Pending data |
Is this your device? Claim it to add documentation and request validation.
Manufacturer
Sources (1)
- FDA UDI 2a09cfe0-4500-4c0f-8851-73a0e093525b 37 fields · synced Jun 8, 2026